Indications
Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency.
Composition
- Active substance
- recombinant human C1-inhibitor
- International name (INN)
- conestat alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ruconest
- Active substance
- recombinant human C1-inhibitor
- ATC code
- B06AC04
- Therapeutic area
- Angioedemas, Hereditary
- Marketing authorisation holder
- Pharming Group N.V.